In Vivo SHIV/SIV Titration via Mucosal Route in Indian-origin Rhesus Macaques

印度恒河猴体内 SHIV/SIV 通过粘膜途径滴定

• 批准号: 9915379
• 负责人: HANNE ANDERSEN
• 金额: $ 15.26万
• 依托单位: BIOQUAL, INC.
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9915379
• 关键词: AIDS Vaccines; Advanced Development; Award; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immunotherapy; Investigator-Initiated Research; Local Microbicides; Macaca mulatta; Modality; Mucous Membrane; National Institute of Allergy and Infectious Disease; Prevention; Prevention strategy; Research Design; Research Personnel; Research Project Grants; Resources; Route; SIV; Titrations; Vaccine Research; Vaccines; Virus; in vivo; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; programs; simian human immunodeficiency virus; vaccine candidate; vaccine development; vaccine evaluation

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers. The primary activity is to conduct an in vivo SHIV or SIV titration via mucosal route in non-human primates.

艾滋病毒疫苗和其他预防策略的开发依赖于在临床前研究中使用非人类灵长类动物，以推动有效的艾滋病疫苗候选疫苗的发展，并促进有效的局部局部杀菌剂和其他预防疗法或免疫疗法的开发。 NIAID Simian疫苗评估单位（SVEU）合同应提供非人类灵长类动物资源，主要支持艾滋病疫苗的临床前评估。 SVEUS进行研究，以支持广泛研究者开发的疫苗。这些研究补充了通过R01（研究人员发起的研究）资助的NIAID支持的基本疫苗研究和疫苗评估研究，HIVRAD（HIV疫苗研究与设计计划）Grants，IPCAVD（综合临床前链式辅助疫苗开发）GRANTS和NHP CONCORTIUM ACHADARDS。 SVEU还对公司或其他研究人员提供的候选疫苗进行研究。 主要活性是通过非人类灵长类动物的粘膜途径进行体内SHIV或SIV滴定。